Omeros earnings date
Omeros (3O8) Q3 2026 Earnings Report
DE:3O8 Q3 2026 EPS Results
- Actual EPS
- -EUR 0.72
- Consensus EPS
- EUR 0.02
- Beat/Miss
- Missed by -EUR 0.74
- One Year Ago EPS
- -EUR 0.43
DE:3O8 Q3 2026 Revenue Results
- Actual Revenue
- EUR 32.76M
- Expected Revenue
- EUR 33.98M
- Beat/Miss
- Missed by -EUR 1.23M
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/16/2026
- Time
- After Close
- Conference Call
- Monday, November 16, 2026
Omeros's next earnings date is estimated for April 5, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive, led by rapid YARTEMLEA sales growth, expanding account and P&T adoption, positive operating cash flow, improved adjusted earnings, reimbursement advantages, and progress across multiple pipeline programs. The main negatives were the European regulatory setback, the OMS527 timing delay, higher expected operating expenses, and a large GAAP loss caused by noncash mark-to-market adjustments. Management repeatedly characterized commercial momentum and the company's financial position as strong.
For the fourth quarter of 2026, Omeros expects total operating expenses from continuing operations to be slightly higher than in the third quarter, with research and development expenses expected to increase primarily due to higher spending on YARTEMLEA and OMS805 OncotoX AML, sales and marketing expenses also expected to increase, interest and other income expected to increase primarily reflecting anticipated inventory reimbursements from Novo, interest expense expected to be approximately $6 million, and income from discontinued operations expected to be between $5 million and $6 million, excluding noncash remeasurement adjustments related to the OMIDRIA contract royalty asset; the company will not be guiding to fourth quarter results, but said YARTEMLEA revenues and growth momentum have continued in Q4 and that it does not expect its $13.3 million positive operating cash flow to change in Q4, while it expects to begin providing guidance at some point in 2027, complete Novo transition services by mid-2027, begin OMS527 inpatient-trial enrollment in early 2027 and still expects clinical-trial data in 2027, begin two YARTEMLEA studies at the end of this year or early next with each designed to enroll approximately 50 to 60 patients, and target a first-in-human OMS805 trial for late 2027.
- Strong YARTEMLEA Commercial MomentumYARTEMLEA generated $41.8 million in gross sales and $35.9 million in net sales in the third quarter, its second full quarter of sales. Gross sales increased 30% from $32.2 million in the second quarter, while net sales increased 26% from $28.5 million. Management said revenue growth continued into the fourth quarter.
- Positive Operating Cash Flow and Improved Adjusted EarningsThe company generated $13.3 million in net cash from operating activities in the third quarter, following $4.1 million in the second quarter and marking its second consecutive quarter of positive operating cash flow. Non-GAAP adjusted net income increased 161% from the second quarter to $4.7 million, or $0.06 per share, from $1.8 million, or $0.02 per share.
- Strengthened Capital StructureOmeros repurchased $30.5 million in aggregate principal amount of its 2029 convertible notes for $60.2 million, reducing outstanding principal by 43% from $70.8 million to $40.3 million. The transactions reduced potential dilution from 11.4 million shares to 6.5 million shares, eliminated $8.6 million in future interest payments, and reduced contractual cash interest expense by $600,000 sequentially to $1.1 million.
- Solid Liquidity PositionOmeros ended the third quarter with $95.3 million in cash and investments. Management said positive operating cash flow and expected revenues from the Novo transaction put the company in a strong financial position and supported continued funding of its programs.
- Expansion of YARTEMLEA Adoption Across Transplant CentersAs of September 30, 109 unique accounts had ordered YARTEMLEA, up 49% from 73 accounts at June 30. The field sales team is engaging all 175 U.S. transplant centers, and P&T committee approvals increased 25% during the third quarter, reaching 80% of the top 40 U.S. transplant centers.
- Increasing Adult and Outpatient UtilizationAdult patients accounted for approximately 70% of YARTEMLEA utilization and pediatric patients for 30%, moving toward the historical nationwide allogeneic transplant mix of 85% adult and 15% pediatric procedures. Outpatient utilization increased, reflected in higher 340B participation, and management said the shift was encouraging for patients and transplant centers.
- Reimbursement Advantages From NTAP and Pass-Through StatusYARTEMLEA became eligible for a new technology add-on payment effective October 1, providing up to $287,000 in additional Medicare reimbursement per eligible inpatient case. Medicare beneficiaries represent approximately 30% of U.S. allogeneic transplant recipients. YARTEMLEA also retains pass-through status through June 2029 and will remain reimbursed at ASP plus 6%, or ASP plus 4.3% after sequestration, rather than being subject to the January 1, 2027 340B reimbursement reduction to ASP minus 28%.
- Broad Payer Coverage and Commercial Reimbursement ProgressManagement stated that all appropriate claims of which it was aware had been paid by commercial payers, Medicare, or Medicaid, with coverage fully aligned with the product label. The company also highlighted that YARTEMLEA's higher price per dose produces greater dollar margins per dose than lower-priced off-label alternatives for commercially insured patients.
- Expanded Education and Field SupportOmeros added 10 positions to its field-force educational team during the prior six weeks, including market development managers, medical science liaisons, and a six-nurse clinical nurse educator team. The company is also establishing a nephrology speaker bureau to expand education about YARTEMLEA and lectin pathway biology.
- Growing Clinical and Economic Evidence for YARTEMLEAThe company is finalizing an HEOR manuscript for journal submission within the next few weeks. Its analyses show favorable incremental cost-effectiveness ratios for YARTEMLEA compared with best supportive care, eculizumab, and ravulizumab. Management also cited publications and manuscripts reporting responses including resolution of organ dysfunction and discontinuation of dialysis.
- Recognition and Upcoming Medical-Meeting VisibilityThe National Organization for Rare Disorders honored Omeros with its 2026 Industry Innovation Award for YARTEMLEA. At the upcoming American Society of Hematology Annual Congress, a presentation will report consistent responses across three cohorts totaling 71 adult and pediatric patients with high-risk TA-TMA, and Omeros will sponsor a continuing medical education session on endothelial injury, complement, and TA-TMA.
- International Expansion and Additional YARTEMLEA IndicationsOmeros is pursuing regulatory approvals outside the European Union and fully reimbursed named-patient programs in parts of Europe and other regions. The company is also evaluating YARTEMLEA in additional transplant-related disorders and plans two open-label single-arm studies with historical controls, one in hyperinflammatory ARDS and one to prevent TA-TMA in high-risk pediatric transplant patients, each designed to enroll approximately 50 to 60 patients.
- Progress on the MASP-2 PlatformThe Phase II-ready long-acting MASP-2 antibody OMS1029 and the oral MASP-2 small-molecule program are advancing toward chronic indications. Omeros is finalizing the initial Phase II indication for OMS1029, and clinical drug product and matching placebo have been manufactured and are available for Phase II trials.
- Novo Collaboration Provides Milestone and Royalty PotentialThe collaboration with Novo remains on track. Omeros received a $240 million upfront payment at the late-2025 transaction closing and remains eligible for more than $1.8 billion in development and commercial milestones, including $100 million in near-term milestone payments, plus tiered royalties on net sales. Transition services are being reimbursed by Novo and are expected to be completed by mid-2027.
- Advancement of OMS527 Clinical DevelopmentThe OMS527 PDE7 inhibitor program for cocaine use disorder remains fully funded by a NIDA grant. Additional nonclinical work requested by the FDA is underway and expected to be completed this month, with enrollment in the inpatient clinical trial now expected to begin in early 2027 and clinical data still expected in 2027.
- Progress in TCAP and Oncology PlatformsIND-enabling studies have begun for the targeted complement-activating therapy platform, which produced complete protection and bacterial clearance in translationally relevant murine models of sepsis and pneumonia caused by multiple drug-resistant bacterial species. In the oncology platform, OMS805 demonstrated up to a 99% selective, reversible, and dose-dependent reduction in target myeloid progenitor cells in nonhuman primates, was well tolerated, and has a first-in-human trial targeted for late 2027.
DE:3O8 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 05, 2027 | 2026 (Q4) | 0.15- | 0.57 | ― | ― |
| Nov 16, 2026 | 2026 (Q3) | 0.02-0.72 | -0.43 | -68.09% (-0.29) | |
| Aug 12, 2026 | 2026 (Q2) | -0.240.14 | -0.39 | 134.88% (+0.53) | |
| May 13, 2026 | 2026 (Q1) | ―- | -0.53 | ― | |
| Mar 31, 2026 | 2025 (Q4) | -0.350.57 | -0.53 | 206.90% (+1.09) | |
| Nov 13, 2025 | 2025 (Q3) | -0.41-0.43 | -0.51 | 16.07% (+0.08) | |
| Aug 14, 2025 | 2025 (Q2) | -0.46-0.39 | -0.88 | 55.67% (+0.49) | |
| May 15, 2025 | 2025 (Q1) | ―-0.53 | -0.57 | 7.94% (+0.05) | |
| Mar 31, 2025 | 2024 (Q4) | -0.52-0.53 | -0.57 | 7.94% (+0.05) | |
| Nov 13, 2024 | 2024 (Q3) | -0.64-0.51 | -0.55 | 6.67% (+0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

